Log In
Print this Print this


  Manage Alerts
Collapse Summary General Information
Company Asana BioSciences LLC
DescriptionExtracellular signal-related kinases (ERK 1/2) inhibitor
Molecular Target MAP kinase 1 (MAPK1) (ERK-2) ; MAP kinase 3 (MAPK3) (ERK-1)
Mechanism of ActionMAP kinase (p38) inhibitor
Therapeutic Modality 
Latest Stage of DevelopmentPreclinical
Standard Indication Cancer (unspecified)
Indication DetailsTreat various cancer
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today